The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM D

OMB APPROVAL OMB Number: Estimated average burden hours per response:

Notice of Exempt Offering of Securities

1. Issuer's Identity			
CIK (Filer ID Number)	Previous Names	X None	Entity Type
0001446847			X Corporation
Name of Issuer			Limited Partnership
IRONWOOD PHARMACEUTICALS I	NC		Limited Liability Company
Jurisdiction of Incorporation/Organia	zation		
DELAWARE			General Partnership
Year of Incorporation/Organization			Business Trust
X Over Five Years Ago			Other (Specify)
Within Last Five Years (Specify	Year)		
Yet to Be Formed			
2. Principal Place of Business and	d Contact Information		
Name of Issuer			
IRONWOOD PHARMACEUTICALS I	NC		
Street Address 1		Street Address 2	
320 BENT STREET			
City St	ate/Province/Country	ZIP/PostalCode	Phone Number of Issuer
CAMBRIDGE M.	A	02141	617-621-7722
3. Related Persons			
Last Name	First Name		Middle Name
EBERSMAN	DAVID		Middle Name
Street Address 1	Street Address 2		
C/O IRONWOOD PHARMACEUTICA	AT S		
INC.	320 BENT STREET		
City	State/Province/Cou	intry	ZIP/PostalCode
CAMBRIDGE	MA		02141
Relationship: Executive Officer	X Director Promoter		
Clarification of Response (if Necess	ary):		
Last Name	First Name		Middle Name
HECHT	PETER		
Street Address 1	Street Address 2		M.
C/O IRONWOOD PHARMACEUTICA	AT C		
INC.	320 BENT STREET		
City	State/Province/Cou	intry	ZIP/PostalCode
CAMBRIDGE	MA		02141
Relationship: X Executive Officer	X Director Promoter		
Clarification of Response (if Necess	ary):		
Last Name	First Name		Middle Name
HIGGINS	MICHAEL		J.

Street Address 1 Street Address 2 C/O IRONWOOD PHARMACEUTICALS, 320 BENT STREET ZIP/PostalCode City State/Province/Country **CAMBRIDGE** 02141 MA Relationship: X Executive Officer | Director Promoter Clarification of Response (if Necessary): Last Name First Name Middle Name **JOSEPH** COOK, JR. C. Street Address 1 Street Address 2 C/O IRONWOOD PHARMACEUTICALS, 320 BENT STREET INC. City State/Province/Country ZIP/PostalCode CAMBRIDGE 02141 MA Executive Officer X Director Relationship: Promoter Clarification of Response (if Necessary): First Name Last Name Middle Name **KNIGHT STEPHEN** Street Address 1 Street Address 2 C/O IRONWOOD PHARMACEUTICALS, 320 BENT STREET INC. State/Province/Country ZIP/PostalCode City **CAMBRIDGE** 02141 MA Executive Officer X Director Promoter Relationship: Clarification of Response (if Necessary): Last Name First Name Middle Name **MCGUIRE TERRANCE** G. Street Address 1 Street Address 2 C/O IRONWOOD PHARMACEUTICALS, 320 BENT STREET State/Province/Country ZIP/PostalCode City **CAMBRIDGE** 02141 Relationship: Executive Officer X Director Promoter Clarification of Response (if Necessary): Last Name First Name Middle Name **MILLER GINA BORNINO** Street Address 1 Street Address 2 C/O IRONWOOD PHARMACEUTICALS, 320 BENT STREET INC. City State/Province/Country ZIP/PostalCode **CAMBRIDGE** MA 02141 Relationship: Executive Officer X Director Promoter Clarification of Response (if Necessary): First Name Middle Name Last Name **ROBERTS BRYAN** E. Street Address 1 Street Address 2 C/O IRONWOOD PHARMACEUTICALS, 320 BENT STREET INC. City State/Province/Country ZIP/PostalCode **CAMBRIDGE** MA 02141

Relationship: Executive Officer X Direction	ector Promoter		
Clarification of Response (if Necessary):			
Last Name WALSH Street Address 1 C/O IRONWOOD PHARMACEUTICALS, INC.	First Name CHRISTOPHER Street Address 2 320 BENT STREET	Middle Name T.	
City	State/Province/Country	ZIP/PostalCode	
CAMBRIDGE	MA	02141	
Relationship: Executive Officer X Direction	ector Promoter		
Clarification of Response (if Necessary):			
Last Name SHAW Street Address 1	First Name DAVID Street Address 2	Middle Name	
C/O IRONWOOD PHARMACEUTICALS, INC.	320 BENT STREET		
City CAMBRIDGE	State/Province/Country MA	ZIP/PostalCode 02141	
Relationship: Executive Officer X Direction	ector Promoter		
Clarification of Response (if Necessary):			
Last Name CONRADES Street Address 1 C/O IRONWOOD PHARMACEUTICALS,	First Name GEORGE Street Address 2 320 BENT STREET	Middle Name H.	
INC. City	State/Province/Country	ZIP/PostalCode	
CAMBRIDGE	MA	02141	
Relationship: Executive Officer X Direction	ector Promoter		
Clarification of Response (if Necessary):			
Last Name CURRIE Street Address 1 C/O IRONWOOD PHARMACEUTICALS, INC.	First Name MARK Street Address 2 320 BENT STREET	Middle Name G.	
City	State/Province/Country	ZIP/PostalCode	
CAMBRIDGE	MA	02141	
Relationship: X Executive Officer Direction	ector Promoter		
Clarification of Response (if Necessary):			
4. Industry Group			
4. muustry Group			

Agriculture	Health Care Retailing
Banking & Financial Services	Biotechnology
Commercial Banking	Health Insurance Technology
Insurance	Hospitals & Physicians Computers
Investing	
Investment Banking	
Pooled Investment Fund	Other Health Care Other Technology
Is the issuer registered as an investment company under	Manufacturing Travel
the Investment Company	Real Estate Airlines & Airports
Act of 1940?	Commercial Lodging & Conventions
∐Yes ∐No	Construction Tourism & Travel Services
Other Banking & Financial Services	REITS & Finance Other Travel
Business Services	Residential
Energy	Other Real Estate
Coal Mining	
Electric Utilities	
Energy Conservation	
Environmental Services	
☐ Oil & Gas	
Other Energy	
5. Issuer Size	
	A
Revenue Range OR No Revenues	Aggregate Net Asset Value Range No Aggregate Net Asset Value
INO Revenues	I INO Aqqieqale inel Assel value
\$1 - \$1,000,000	\$1 - \$5,000,000
\$1 - \$1,000,000 \$1,000,001 - \$5,000,000	\$1 - \$5,000,000 \$5,000,001 - \$25,000,000
\$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000	\$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000
\$1 - \$1,000,000 \$1,000,001 - \$5,000,000	\$1 - \$5,000,000 \$5,000,001 - \$25,000,000
\$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 -	\$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000
\$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 X Decline to Disclose	\$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000
\$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000	\$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000
\$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 X Decline to Disclose	\$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable
\$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 X Decline to Disclose Not Applicable	\$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable
\$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 X Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s) Cla	\$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply)
\$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 X Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s) Cla	\$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply)
\$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 X Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s) Cla	\$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply) Rule 505 X Rule 506
\$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 X Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s) Cla Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii)	\$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply) Rule 505 X Rule 506 Securities Act Section 4(5)
\$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 X Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s) Cla Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii)	\$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply) Rule 505 X Rule 506 Securities Act Section 4(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(9)
\$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 X Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s) Cla Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii)	\$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply) Rule 505 X Rule 506 Securities Act Section 4(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(2) Section 3(c)(10)
\$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 X Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s) Cla Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii)	\$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply) Rule 505 X Rule 506 Securities Act Section 4(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(2) Section 3(c)(10) Section 3(c)(11) Section 3(c)(11)
\$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 X Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s) Cla Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii)	\$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply) Rule 505 X Rule 506 Securities Act Section 4(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(2) Section 3(c)(10)
\$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 X Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s) Cla Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii)	\$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply) Rule 505 X Rule 506 Securities Act Section 4(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(2) Section 3(c)(10) Section 3(c)(11) Section 3(c)(11)
\$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 X Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s) Cla Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii)	\$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable imed (select all that apply) Rule 505 X Rule 506 Securities Act Section 4(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(2) Section 3(c)(1)
\$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$100,000,000 Over \$100,000,000 X Decline to Disclose Not Applicable 6. Federal Exemption(s) and Exclusion(s) Cla Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii)	\$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 \$50,000,001 - \$100,000,000 Over \$100,000,000 Decline to Disclose Not Applicable Imed (select all that apply) Rule 505 X Rule 506 Securities Act Section 4(5) Investment Company Act Section 3(c) Section 3(c)(1) Section 3(c)(2) Section 3(c)(10) Section 3(c)(11) Section 3(c)(4) Section 3(c)(12) Section 3(c)(13)

7. Type of Filing		
X New Notice Date of First Sale 2009-09-01 First Sale Yet to Amendment	o Occur	
8. Duration of Offering		
Does the Issuer intend this offering to last more than one year?	Yes X No	
9. Type(s) of Securities Offered (select all that apply)		
 X Equity Debt Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant or ORight to Acquire Security 	Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities Other (describe)	
10. Business Combination Transaction		
Is this offering being made in connection with a business combina merger, acquisition or exchange offer?	tion transaction, such as a Yes X No	
Clarification of Response (if Necessary):		
11. Minimum Investment		
Minimum investment accepted from any outside investor \$24,999,	996 USD	
12. Sales Compensation		
Recipient (Associated) Broker or Dealer X None Street Address 1 City State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Recipient CRD Number X None (Associated) Broker or Dealer CRD Number X None Street Address 2 State/Province/Country Foreign/non-US	ZIP/Postal Code
13. Offering and Sales Amounts		
Total Offering Amount \$24,999,996 USD or Indefinite Total Amount Sold \$24,999,996 USD Total Remaining to be Sold \$0 USD or Indefinite Clarification of Response (if Necessary):		
14. Investors		
Select if securities in the offering have been or may be sold to enter the number of such non-accredited investors who alread Regardless of whether securities in the offering have been or investors, enter the total number of investors who already have	y have invested in the offering. may be sold to persons who do not qualify as accredited	
15. Sales Commissions & Finder's Fees Expenses		
Provide separately the amounts of sales commissions and finders estimate and check the box next to the amount.	fees expenses, if any. If the amount of an expenditure is no	ot known, provide an
Sales Commissions \$0 USD Estimate		
Finders' Fees \$0 USD Estimate		
Clarification of Response (if Necessary):		
16. Use of Proceeds		

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to
be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the
box next to the amount

\$0 USD Estimate	
Clarification of Response (if Necessary):	

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to

Terms of Submission

file this notice.

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
IRONWOOD PHARMACEUTICALS INC	HALLEY GILBERT	HALLEY GILBERT	GENERAL COUNSEL	2009-09-03

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.